Susanna L. Cooke

Susanna L. Cooke

Auto-generated profile, based on publicly available information

Susanna L. Cooke

University of Glasgow, Glasgow, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
SDStephan B Dreyer
Stephan B Dreyer
RURosie Upstill-Goddard
Rosie Upstill-Goddard
VPViola Paulus-Hock
Viola Paulus-Hock
CPClara Paris
Clara Paris
ELEirini-Maria Lampraki
Eirini-Maria Lampraki
DCDavid K Chang
David K Chang
Background & Aims Continuing recalcitrance to therapy cements pancreatic cancer (PC) as the most lethal malignancy, which is set to become the second leading cause of cancer death in our society. The study aim was to investigate the association between DNA damage response (DDR), replication stress, and novel therapeutic response in PC to develop a biomarker-driven therapeutic strategy targeting DDR and replication stress in PC. Methods We interrogated the transcriptome, genome, proteome, and functional characteristics of 61 novel PC patient–derived cell lines to define novel therapeutic strategies targeting DDR and replication stress. Validation was done in patient-derived xenografts and human PC organoids. Results Patient-derived cell lines faithfully recapitulate the epithelial component of pancreatic tumors, including previously described molecular subtypes. Biomarkers of DDR deficiency, including a novel signature of homologous recombination deficiency, cosegregates with response to platinum (P < .001) and PARP inhibitor therapy (P < .001) in vitro and in vivo. We generated a novel signature of replication stress that predicts response to ATR (P < .018) and WEE1 inhibitor (P < .029) treatment in both cell lines and human PC organoids. Replication stress was enriched in the squamous subtype of PC (P < .001) but was not associated with DDR deficiency. Conclusions Replication stress and DDR deficiency are independent of each other, creating opportunities for therapy in DDR-proficient PC and after platinum therapy.

7 January 2021 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
KHKaren D. Howarth
Karen D. Howarth
TMTashfina Mirza
Tashfina Mirza
SCSusanna L. Cooke
Susanna L. Cooke
SCSuet-Feung Chin
Suet-Feung Chin
JPJessica C. Pole
Jessica C. Pole
PEPaul A. W. Edwards
Paul A. W. Edwards
Background: NRG1gene fusions may be clinically actionable, since cancers carrying the fusion transcripts can be sensitive to tyrosine kinase inhibitors. TheNRG1gene encodes ligands for the HER2(ERBB2)-ERBB3 heterodimeric receptor tyrosine kinase, and the gene fusions are thought to lead to autocrine stimulation of the receptor. TheNRG1fusion expressed in the breast cancer cell line MDA-MB-175 serves as a model example of such fusions, showing the proposed autocrine loop and exceptional drug sensitivity. However, its structure has not been properly characterised, its oncogenic activity has not been fully explained, and there is limited data on such fusions in breast cancer.Methods: We analysed genomic rearrangements and transcripts ofNRG1in MDA-MB-175 and a panel of 571 breast cancers.Results: We found that the MDA-MB-175 fusion—originally reported as aDOC4(TENM4)-NRG1fusion, lacking the cytoplasmic tail ofNRG1—is in reality a double fusion,PPP6R3-TENM4-NRG1, producing multiple transcripts, some of which include the cytoplasmic tail. We hypothesise that manyNRG1fusions may be oncogenic not for lacking the cytoplasmic domain but because they do not encode NRG1’s nuclear-localised form. The fusion in MDA-MB-175 is the result of a very complex genomic rearrangement, which we partially characterised, that creates additional expressed gene fusions,RSF1-TENM4,TPCN2-RSF1, andMRPL48-GAB2.We searched forNRG1rearrangements in 571 breast cancers subjected to genome sequencing and transcriptome sequencing and found four cases (0.7%) with fusions,WRN-NRG1,FAM91A1-NRG1,ARHGEF39-NRG1, andZNF704-NRG1, all splicing intoNRG1at the same exon as in MDA-MB-175. However, theWRN-NRG1andARHGEF39-NRG1fusions were out of frame. We identified rearrangements ofNRG1in many more (8% of) cases that seemed more likely to inactivate than to create activating fusions, or whose outcome could not be predicted because they were complex, or both. This is not surprising becauseNRG1can be pro-apoptotic and isinactivated in some breast cancers.Conclusions: Our results highlight the complexity of rearrangements ofNRG1in breast cancers and confirm that some do not activate but inactivate. Careful interpretation ofNRG1rearrangements will therefore be necessary for appropriate patient management.

7 October 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
GHGwo Yaw Ho
Gwo Yaw Ho
EKElizabeth L. Kyran
Elizabeth L. Kyran
JBJustin Bedo
Justin Bedo
MWMatthew J. Wakefield
Matthew J. Wakefield
DEDarren P. Ennis
Darren P. Ennis
HBHolly Barker
Holly Barker
Ovarian carcinosarcoma (OCS) is an aggressive and rare tumor type with limited treatment options. OCS is hypothesized to develop via the combination theory, with a single progenitor resulting in carcinomatous and sarcomatous components, or alternatively via the conversion theory, with the sarcomatous component developing from the carcinomatous component through epithelial-to-mesenchymal transition (EMT). In this study, we analyzed DNA variants from isolated carcinoma and sarcoma components to show that OCS from 18 women is monoclonal. RNA sequencing indicated that the carcinoma components were more mesenchymal when compared with pure epithelial ovarian carcinomas, supporting the conversion theory and suggesting that EMT is important in the formation of these tumors. Preclinical OCS models were used to test the efficacy of microtubule-targeting drugs, including eribulin, which has previously been shown to reverse EMT characteristics in breast cancers and induce differentiation in sarcomas. Vinorelbine and eribulin more effectively inhibited OCS growth than standard-of-care platinum-based chemotherapy, and treatment with eribulin reduced mesenchymal characteristics and N-MYC expression in OCS patient-derived xenografts. Eribulin treatment resulted in an accumulation of intracellular cholesterol in OCS cells, which triggered a downregulation of the mevalonate pathway and prevented further cholesterol biosynthesis. Finally, eribulin increased expression of genes related to immune activation and increased the intratumoral accumulation of CD8+ T cells, supporting exploration of immunotherapy combinations in the clinic. Together, these data indicate that EMT plays a key role in OCS tumorigenesis and support the conversion theory for OCS histogenesis. Targeting EMT using eribulin could help improve OCS patient outcomes. Significance: Genomic analyses and preclinical models of ovarian carcinosarcoma support the conversion theory for disease development and indicate that microtubule inhibitors could be used to suppress EMT and stimulate antitumor immunity.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
PBPhilip A. Beer
Philip A. Beer
SCSusanna L. Cooke
Susanna L. Cooke
XLXuan Shirley Li
Xuan Shirley Li
ABAndrew V. Biankin
Andrew V. Biankin
Distinguishing genomic events that drive cancer (drivers) from inconsequential damage (passengers) is key to matching patients with biomarker-associated therapies and clinical trials. Whilst population level genomic analyses can estimate the proportion of driver events within a given gene, they cannot categorize individual variants. Reliable annotation remains a significant barrier to unlocking the full utility of cancer genomics. GENIE (Genomics Evidence Neoplasia Information Exchange) data was used to generate codon recurrence scores (CRS) for known cancer genes. GENIE was parsed to remove duplicates, sequencing artefact (recurrent variants reported by one institution, invariably associated with amplicon-based sequencing) and hypermutated samples (>15 mutations per megabase). For missense mutations, a codon recurrence of ≥10 was used to classify driver mutations. The table shows proportion of missense mutations classified as drivers by gene and cancer type, comparing population-based non-synonymous to synonymous mutation ratio; dN/dS (Martincorena 2017, PMID 29056346) with assessment of individual variants by CRS. This comparison demonstrates a high degree of concordance. For a few genes, CRS under called driver mutations (ie VHL in renal cancer) likely due to reduced power with small sample numbers. Importantly, CRS is able to assign driver status to individual missense mutations. Comparison with informatic analyses (PMIDs 28115009, 29247016, 30365005, 31034466) showed equivalent or superior performance of the GENIE approach. These findings demonstrate how a large (and expanding) real-world dataset can be used to predict the driver status of somatic missense mutations at the n=1 variant level. This process is amenable to implementation as a rules-based classification process for somatic missense mutations as part of an automated annotation pipeline. Citation Format: Philip A. Beer, Susanna L. Cooke, Xuan Shirley Li, Andrew V. Biankin. Leveraging the GENIE dataset to distinguish somatic cancer drivers from passenger events in routine oncology practice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1176.